New combo therapy aims to beat tough leukemia
NCT ID NCT07203352
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 22 times
Summary
This study tests whether adding a new targeted drug to standard chemotherapy helps adults with newly diagnosed acute T-lymphocytic leukemia live longer. About 154 participants will be randomly assigned to get either the new combo or chemo alone. The main goal is to see if the combo improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology,Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.